linjc16/ctgov huggingface dataset:
Clinical Significance of Marginal Acute Inflammation for Stage II Colon Cancer

Study Overview
=================
Brief Summary
-----------------
Marginal acute inflammation would make reporting the serosal involvement of tumors controversial. We aimed to investigate the clinical significance and explore the prognostic value of MAI for stage II localized colon cancer.

Official Title
-----------------
Presence and Clinical Significance of Marginal Acute Inflammation for Stage II Colon Cancer

Conditions
-----------------
Inflammation, Colon Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: MAI detection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: (1) colon cancer patients with the preoperative staging of stage I-III who lacked distant metastasis; (2) patients who underwent radical resection, with postoperative pathology confirmed as pT3-4N0M0; and (3) complete follow-up information Exclusion Criteria: (1) patients who received neo-adjuvant therapy; (2) patients with multiple primary colorectal cancer; and (3) patients with a history of malignant tumors

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| T3<br>patient staged T3 without marginal acute inflammation | Diagnostic Test: MAI detection<br>* to detect the presence of marginal acute inflammation<br>|
| MAI<br>patient with marginal acute inflammation | Diagnostic Test: MAI detection<br>* to detect the presence of marginal acute inflammation<br>|
| T4<br>patient staged T4 without marginal acute inflammation | Diagnostic Test: MAI detection<br>* to detect the presence of marginal acute inflammation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DFS | disease free survival | 5 year |
Call to Door Timing in Out-of-hospital Cardiac Arrest

Study Overview
=================
Brief Summary
-----------------
The investigators aimed to investigate the effect of delayed hospitalization on the basis of the call time on the clinical outcomes of patients with OHCA patients using a nationwide OHCA registry.

Detailed Description
-----------------
According to 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care, immediate call for the local emergency response number takes a key role in the OHCA as the CPR in community does not provide quality of in-hospital CPR. The strong recommendation of speedy transportation, however, does not provide time limitation, and evident data supporting benefit within certain minutes to transfer is lack through our best of search. Therefore, The investigators aimed to investigate the effect of delayed hospitalization on the basis of the call time on the clinical outcomes of patients with OHCA patients using a nationwide OHCA registry.

Official Title
-----------------
Clinical Impact in Patients With Delayed Hospitalization in Patients With Out-of-hospital Cardiac Arrest

Conditions
-----------------
Cardiac Arrest, Morality

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Out-of-hospital cardiac arrest event Exclusion Criteria: Arrest of non-cardiac origin Age < 18 years No any CPR Missing data on call time

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cardiac Arrest<br>Out-Of-Hospital Cardiac Arrest | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Death from any cause at hospital discharge | Death from any cause at hospital discharge | up to 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Poor neurological outcomesat hospital discharge | poor neurological outcomes, which was defined as a Glasgow-Pittsburge Cerebral Performance Category value at hospital discharge | up to 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cardiac arrest, Mortality, Timing
Factors Associated With Recurrent Falls in Stroke Patients

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to learn about the recurrent falls in patients with acute stroke. The main question[s] it aims to answer are: what is the frequency of recurrent falls which factors are associated with recurrent falls in patients with acute stroke. Participants will be evaluated in terms of frequency of recurrent falls within the six months after stroke fear of falling the stroke severity (Canadian Neurological Scale), ambulation level (Functional Ambulation Classification), functional disability (Functional Independence Scale) Postural control and balance functional status (Modified Rankin Scale)

Detailed Description
-----------------
Falling is common in stroke patients both in the hospital and at home after discharge. As a result, physical problems such as fractures and psychological problems such as fear of falling, limitation of physical activity and social isolation occur. Identifying the factors that cause falls after stroke will contribute to the recovery process by preventing complications by taking the necessary precautions and increasing the patient's participation in rehabilitation. This study was planned to determine the frequency of falls in patients with acute stroke and to determine the risk factors associated with recurrent falls within the first six months after stroke.

Official Title
-----------------
Frequency of Falls in Stroke Patients and Factors Associated With Recurrent Falls

Conditions
-----------------
Fall, Stroke

Intervention / Treatment
-----------------
* Other: Fall evaluation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Having an acute stroke over the age of 18 To have a cognitive situation to understand and answer questions Exclusion Criteria: Patients with bilateral hemiplegia Patients without motor involvement Those with a history of stroke Patients with severe cognitive impairment Patients in need of intensive care

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Fall evaluation|Evaluation of the frequency of falls in patients with acute stroke and determining the risk factors associated with recurrent falls within the first six months after stroke|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of fall | The frequency of recurrent falls were were determined by questioning the patients. | Six month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Factors related with recurrent falls | Poor postural control, number of falls,fear of falling, functional disability, ambulation level of the patients will be evaluated. | Six month |
Changes in Hemorrhage With Prophylactic Oxytocin for Dilation and Evacuation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the effectiveness of prophylactic oxytocin on hemorrhage rates for second trimester dilation and evacuation (D&E) in the clinic setting.

Official Title
-----------------
Changes in Rate of Hemorrhage With Prophylactic Oxytocin for Second Trimester Dilation and Evacuation in the Clinic Setting

Conditions
-----------------
Hemorrhage

Intervention / Treatment
-----------------
* Drug: Oxytocin + normal saline
* Drug: Normal saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinic-based D&E at 18 weeks gestational age and above speaks English or Spanish Exclusion Criteria: refuses IV history of coagulopathy anticoagulant use in the preceding five days chorioamnionitis or sepsis suspected placenta accreta spectrum intrauterine fetal demise multiple gestation use of misoprostol for cervical preparation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Randomized controlled trial - randomized to either receive treatment (40 units IV oxytocin + 1000 mL normal saline) or placebo (1000 mL normal saline alone).
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Oxytocin<br>Participants receive 40 units IV oxytocin in 1000 mL of normal saline at the time of tenaculum placement for D&E. | Drug: Oxytocin + normal saline<br>* 40 units IV oxytocin once in a 1000 mL bag of normal saline<br>|
| Placebo Comparator: Placebo<br>Participants receive 1000 mL of normal saline alone at the time of tenaculum placement for D&E. | Drug: Normal saline<br>* 1000 mL bag of normal saline alone<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hemorrhage | Quantitative blood loss greater than or equal to 500 mL or a clinical response to excessive bleeding such as transfusion or hospital admission | day of procedure | 
| Quantitative blood loss | Measured blood loss during procedure | day of procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Procedure time | Length of time of total procedure and length of time until bleeding initially managed | day of procedure |
Evaluation of Clinical and Pathological Characteristics and Routine Treatment of Patients With Prostate Cancer

Study Overview
=================
Brief Summary
-----------------
To evaluate clinical and pathological characteristics and treatment protocol and outcomes of patients with prostate cancer in 2 centers of Asyut from 2013 to 2023

Detailed Description
-----------------
Inclusion criteria : Male patient , Age ≥ 40 yo Diagnosed as prostate cancer from ( 2013- 2023 ) proved by biopsy in South Egypt Cancer Institute SECI & Asyut clinical oncology department Newly diagnosed/ metastatic at presentation ECOG 0-4 • Exclusion criteria: Having Other types of malignancy.

Official Title
-----------------
Evaluation of Clinical and Pathological Characteristics and Routine Treatment of Patients With Prostate Cancer in 2 Centers in Asyut

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Radiation: Radiotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male patient , Age ≥ 40 yo Diagnosed as prostate cancer from ( 2013- 2023 ) proved by biopsy Newly diagnosed/ metastatic at presentation ECOG 0-4 Exclusion Criteria: Having Other types of malignancy.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Radiation: Radiotherapy|Effect of radiotherapy on patients|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical and pathological characteristics and routine treatment of patients with prostate cancer in 2 centers in Asyut in previous 10 years | Clinical and pathological characteristics and routine treatment of patients with prostate cancer in 2 centers in Asyut in previous 10 years | Baseline |
Short Term Outcomes in Hospitalized Patients With Liver Cirrhosis

Study Overview
=================
Brief Summary
-----------------
This study will be conducted to assess the baseline characteristics and evaluate the 90-day mortality of patients admitted with liver cirrhosis. Also, the study will be done to identify the risk factors of 90-day mortality.

Detailed Description
-----------------
Liver cirrhosis is the end spectrum of all chronic liver diseases characterized by advanced fibrosis, scarring, and formation of regenerative nodules leading to hepatic architectural distortion. Liver cirrhosis is a major cause of health burden worldwide. According to the Global Burden of Disease study, liver cirrhosis caused 1.2% of global disability-adjusted life years and 2% of all deaths worldwide in 2010, the 14th leading cause of mortality. The progress rate of compensated cirrhosis to decompensated cirrhosis is approximately 58% and once it progresses to decompensated cirrhosis, its mortality rate within 5 years becomes 85% without liver transplantation. Since the progression of cirrhosis is accelerated each time a complication recurs, the management and treatment of the complication are critical in enhancing the quality of life and the life expectancy of patients . Post-discharge outcomes are an integral component of healthcare, as they may aid in determining the success and longevity of treatment and how clinicians approach future cases . This study will focus on the short-term outcomes of patients hospitalized with liver cirrhosis to provide insight into methods for future healthcare interventions.

Official Title
-----------------
Short Term Outcomes in Hospitalized Patients With Liver Cirrhosis

Conditions
-----------------
Liver Cirrhosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - diagnosis of liver cirrhosis, adult (age ≥ 18 years old) and patients willing to give consent during the selected period. Exclusion Criteria: - Patients with ages < 18 years or patients that will be lost on follow-up will be excluded from the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| evaluate the 90-day mortality of patients admitted with liver cirrhosis | Mortality | 90 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| identify the risk factors of 90-day mortalit | Risk factors for mortality | 90 days |
A Study to Access the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)

Study Overview
=================
Brief Summary
-----------------
FOCUS (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with ADHD.

Detailed Description
-----------------
Eligible subjects must have a primary diagnosis of ADHD based on the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria. Subjects will be randomized in a 1:1:1 ratio to be treated with solriamfetol 150 mg, solriamfetol 300 mg, or placebo, once daily for 6 weeks.

Official Title
-----------------
A Phase 3, Randomized, Double-blind, Placebo-controlled Trial of Solriamfetol in Adults

Conditions
-----------------
ADHD

Intervention / Treatment
-----------------
* Drug: Solriamfetol 150 mg
* Drug: Solriamfetol 300 mg
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary diagnosis of ADHD according to DSM-5 criteria. Provides written informed consent to participate in the study before the conduct of any study procedures. Male or female, aged 18 to 55 inclusive. Exclusion Criteria: Prior exposure to solriamfetol/Sunosi, through either a clinical study or prescription. Unable to comply with study procedures. Medically inappropriate for study participation in the opinion of the investigator.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Solriamfetol 150 mg<br>Up to 6 weeks | Drug: Solriamfetol 150 mg<br>* Solriamfetol tablets, taken once daily<br>|
| Experimental: Solriamfetol 300 mg<br>Up to 6 weeks | Drug: Solriamfetol 300 mg<br>* Solriamfetol tablets, taken once daily<br>|
| Placebo Comparator: Placebo<br>Up to 6 weeks | Drug: Placebo<br>* Placebo tablets, taken once daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline to Week 6 in the AISRS total score | Adult ADHD Investigator Symptom Report Scale (AISRS) | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Attention deficit hyperactivity disorder, ADHD, Solriamfetol, Sunosi, Axsome, Non-stimulant therapy, Dopamine norepinephrine reuptake inhibitor
Registry 17-009: Multi-Institutional Study Examining Patients With HCC Undergoing Liver Transplantation

Study Overview
=================
Brief Summary
-----------------
This is a registry study examining patients with HCC undergoing liver transplantation including outcomes and predictors of recurrence

Official Title
-----------------
Registry 17-009: Multi-Institutional Study Examining Patients With HCC Undergoing Liver Transplantation

Conditions
-----------------
Hepatocellular Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients (age>18 years) undergoing Liver transplant for hepatocellular carcinoma Exclusion Criteria: Patients under 18 years old Patients who do not have hepatocellular carcinoma patients who have hepatocellular carcinoma but do not undergo liver transplantation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence Free Survival |  | From date of surgery to date of identified cancer recurrence through either clinical judgement or scans. This is assessed up to 10 years after the surgery. | 
| Overall Survival |  | From date of surgery to date of death, up to 10 years after the surgery. |
The Paternal Clock: Uncovering the Consequences of Advanced Paternal Age on Sperm DNA Fragmentation

Study Overview
=================
Brief Summary
-----------------
Sperm DNA fragmentation (SDF) serves as a marker for chromatin and DNA damage in sperm. Assessing sperm DNA integrity is crucial in male fertility evaluation since high levels of SDF are associated with a greater number of adverse reproductive outcomes, including an increased risk of miscarriage and birth defects. Recent research suggests that advanced paternal age (APA) may lead to DNA damage in sperm, however the precise age at which this risk becomes apparent has not yet been clearly defined, necessitating the identification of the point in time at which high SDF levels occur. With the help of this knowledge, male infertility can be diagnosed with greater accuracy, and infertile couples can receive appropriate care.

Official Title
-----------------
The Paternal Clock: Uncovering the Consequences of Advanced Paternal Age on Sperm DNA Fragmentation

Conditions
-----------------
Infertility, Male

Intervention / Treatment
-----------------
* Other: Study chart review


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male of at least 18 years of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Men undergoing sperm DNA fragmentation test<br>Men presenting at the clinic for infertility evaluation | Other: Study chart review<br>* Evaluation of 4250 sperm DNA fragmentation samples with the goal of defining a cut-off age beyond which SDF levels increase significantly<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Investigate the impact of advanced paternal age on sperm DNA fragmentation | Comparing mean sperm DNA fragmentation throughout the chart review of different age groups | Up to 3 weeks |